Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ enriched, T Cell Depleted donor stem cell product
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ enriched, T Cell Depleted donor stem cell product is an investigational cellular therapy developed for use in pediatric patients undergoing alternative donor hematopoietic stem cell transplantation (HSCT). The product is created by processing donor bone marrow or peripheral blood stem cells using the CliniMACS selection system to selectively enrich for CD34+ hematopoietic stem cells while depleting CD3+ T cells. This approach is designed to provide a sufficient stem cell dose for rapid engraftment while minimizing the risk of Graft-versus-Host Disease (GVHD), which is primarily mediated by donor T cells. This specific protocol, led by Christopher Dvorak at the University of California, San Francisco, focuses on providing expanded access to this transplant method for high-risk children who lack a human leukocyte antigen (HLA)-matched donor.
- Other names
- CD34+ enriched, T Cell Depleted donor stem cell product-Christopher DvorakCliniMACS CD34+ selected cellsT-cell depleted stem cell graft
Beyond the preview
Go deeper on CD34+ enriched, T Cell Depleted donor stem cell product.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ enriched, T Cell Depleted donor stem cell product.